Sapanisertib for Acute Lymphoblastic Leukemia
Trial Summary
What is the purpose of this trial?
This phase II trial studies how well sapanisertib works in treating patients with acute lymphoblastic leukemia that has returned after a period of improvement (relapsed) or has not responded to previous treatment (refractory). Sapanisertib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Research Team
Aref Al-Kali
Principal Investigator
Mayo Clinic Cancer Center LAO
Eligibility Criteria
This trial is for adults with acute lymphoblastic leukemia that's come back or hasn't responded to treatment. They should have controlled blood sugar, no severe active infections, and a life expectancy over 2 months. Pregnant women can't join, and participants must use effective contraception.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive sapanisertib orally daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Extended Treatment
Non-responders and those in partial response at the end of course 4 may receive sapanisertib daily on days 1-28. Courses repeat every 28 days.
Follow-up
Participants are monitored for safety and effectiveness after treatment completion.
Treatment Details
Interventions
- Sapanisertib
Find a Clinic Near You
Who Is Running the Clinical Trial?
National Cancer Institute (NCI)
Lead Sponsor